Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Chlorpromazine Hydrochloride

FDA-approved product (concentrate, oral), marketed as Chlorpromazine Hydrochloride, Chlorpromazine Hydrochloride Intensol, Promapar and 2 more.

Registered studies
33
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Chlorpromazine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Conduct disorder
  • Mental or behavioural disorder
  • Nausea and vomiting
  • Porphyria
  • Psychosis
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Phenothiazines with aliphatic side-chain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA36.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli30.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae13.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis75.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

33registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Chlorpromazine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Chlorpromazine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer

    NCT03021486 · start 2017-06-05

    Registered record
    Registry ID
    NCT03021486
    Conditions
    Advanced Malignant Neoplasm; Delirium; Locally Advanced Malignant Neoplasm; Metastatic Malignant Neoplasm; Recurrent Malignant Neoplasm
    Interventions
    Chlorpromazine; Haloperidol; Quality-of-Life Assessment; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2017-06-05
    Completion
    2027-06-30
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Malignant Neoplasm; Delirium; Locally Advanced Malignant Neoplasm; Metastatic Malignant Neoplasm +1 more
    InterventionChlorpromazine; Haloperidol; Quality-of-Life Assessment; Questionnaire Administration
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • Explorations of the Normal Neural Behavioral and Pathological Bases of Metacognition

    NCT03140475 · start 2017-04-27

    Registered record
    Registry ID
    NCT03140475
    Conditions
    Schizophrenia; Insight Impaired; Social Skills; Behavior
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-04-27
    Completion
    2025-03-05
    Enrolment
    109

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Insight Impaired; Social Skills; Behavior
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride

    NCT02943213 · start 2016-11

    Registered record
    Registry ID
    NCT02943213
    Conditions
    Anti-Psychotic; Management of Manifestations of Psychotic Disorders; Treatment of Schizophrenia; Control Nausea and Vomiting; Relief of Restlessness and Apprehension Before Surgery; Acute Intermittent Porphyria; Adjunct in the Treatment of Tetanus; Control Manifestations of the Manic Type of Mani-depressive Illness; Relief of Intractable Hiccups
    Interventions
    Chlorpromazine Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-11
    Completion
    2016-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnti-Psychotic; Management of Manifestations of Psychotic Disorders; Treatment of Schizophrenia; Control Nausea and Vomiting +5 more
    InterventionChlorpromazine Hydrochloride
    PhasePhase 1
    Registry statusCompleted

  • Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

    NCT02600741 · start 2015-07-24

    Registered record
    Registry ID
    NCT02600741
    Conditions
    Schizophrenia
    Interventions
    Caregiver psycho-education and skills training; Caregiver support available at the study site; Paliperidone palmitate; Chlorpromazine; Droperidol; Fluphenazine; Haloperidol; Loxapine; Perphenazine; Pimozide; Prochlorperazine; Thiothixene; Thioridazine; Trifluoperazine; Aripiprazole; Asenapine; Clozapine; Iloperidone; Olanzapine; Paliperidone; Quetiapine; Risperidone; Ziprasidone
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-07-24
    Completion
    2018-07-05
    Enrolment
    296

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionCaregiver psycho-education and skills training; Caregiver support available at the study site; Paliperidone palmitate; Chlorpromazine +19 more
    PhaseNot recorded
    Registry statusCompleted

  • Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis

    NCT01765829 · start 2012-11

    Registered record
    Registry ID
    NCT01765829
    Conditions
    Psychosis Nos/Other
    Interventions
    Discontinuation antipsychotic treatment; Antipsychotic treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2012-11
    Completion
    2015-11
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychosis Nos/Other
    InterventionDiscontinuation antipsychotic treatment; Antipsychotic treatment
    PhasePhase 3
    Registry statusUnknown

  • Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

    NCT01594749 · start 2012-09-24

    Registered record
    Registry ID
    NCT01594749
    Conditions
    Chemotherapy-Induced Nausea and Vomiting (CINV)
    Interventions
    Fosaprepitant dimeglumine; Fosaprepitant Placebo; Dexamethasone; Ondansetron; Dexamethasone Placebo; Ondansetron Placebo; Rescue Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-09-24
    Completion
    2014-11-03
    Enrolment
    1,015

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy-Induced Nausea and Vomiting (CINV)
    InterventionFosaprepitant dimeglumine; Fosaprepitant Placebo; Dexamethasone; Ondansetron +3 more
    PhasePhase 3
    Registry statusCompleted

  • Antipsychotics and Risk of Hyperglycemic Emergencies

    NCT02582736 · start 2012-04

    Registered record
    Registry ID
    NCT02582736
    Conditions
    Psychotic Disorders; Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Diabetes Mellitus, Type 2
    Interventions
    Olanzapine; Risperidone; atypical antipsychotics (other); typical antipsychotics
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-04
    Completion
    2012-12
    Enrolment
    725,489

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychotic Disorders; Schizophrenia; Schizoaffective Disorder; Bipolar Disorder +1 more
    InterventionOlanzapine; Risperidone; atypical antipsychotics (other); typical antipsychotics
    PhaseNot recorded
    Registry statusCompleted

  • Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia

    NCT01323205 · start 2011-05

    Registered record
    Registry ID
    NCT01323205
    Conditions
    Schizophrenia
    Interventions
    JNJ-40411813; JNJ-40411813; Placebo; Antipsychotic medication
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-05
    Completion
    2012-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionJNJ-40411813; JNJ-40411813; Placebo; Antipsychotic medication
    PhasePhase 2
    Registry statusCompleted

  • Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction

    NCT03019887 · start 2011-04

    Registered record
    Registry ID
    NCT03019887
    Conditions
    Schizophrenia Relapse
    Interventions
    reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-04
    Completion
    2017-01
    Enrolment
    139

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia Relapse
    Interventionreduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine
    PhaseNot applicable
    Registry statusCompleted

  • Cyproheptadine and Chlorpromazine Effects on Spasticity

    NCT01509885 · start 2010-07

    Registered record
    Registry ID
    NCT01509885
    Conditions
    Spinal Cord Injuries; Muscle Spasticity
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-07
    Completion
    2012-11
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpinal Cord Injuries; Muscle Spasticity
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Use of Intravitreal Triamcinolone and Retrobulbar Chlorpromazine as Alternatives to the Management of Painful Blind Eye

    NCT01404364 · start 2010-01

    Registered record
    Registry ID
    NCT01404364
    Conditions
    Blind Painful Eye; Refractory Glaucoma; Control of Pain Through Drug Injection
    Interventions
    Triamcinolone; Chlorpromazine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-01
    Completion
    2010-12
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBlind Painful Eye; Refractory Glaucoma; Control of Pain Through Drug Injection
    InterventionTriamcinolone; Chlorpromazine
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients

    NCT00882518 · start 2009-04

    Registered record
    Registry ID
    NCT00882518
    Conditions
    Schizophrenia
    Interventions
    Quetiapine Fumarate (SEROQUEL) Extended-Release (XR); Chlorpromazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-04
    Completion
    2010-07
    Enrolment
    388

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionQuetiapine Fumarate (SEROQUEL) Extended-Release (XR); Chlorpromazine
    PhasePhase 3
    Registry statusCompleted

  • Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm

    NCT01016145 · start 2009-04

    Registered record
    Registry ID
    NCT01016145
    Conditions
    Schizophrenia or Schizoaffective Disorder
    Interventions
    Antipsychotics; Antipsychotics
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2009-04
    Completion
    2010-07
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia or Schizoaffective Disorder
    InterventionAntipsychotics; Antipsychotics
    PhasePhase 4
    Registry statusUnknown

  • Pragmatic RCT Comparing Aripiprazole, Olanzapine and Haloperidol in the Treatment of Schizophrenia

    NCT01052389 · start 2007-07

    Registered record
    Registry ID
    NCT01052389
    Conditions
    Schizophrenia
    Interventions
    Aripiprazole; Olanzapine; Haloperidol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-07
    Completion
    2013-06
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionAripiprazole; Olanzapine; Haloperidol
    PhasePhase 4
    Registry statusCompleted

  • Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia

    NCT00654576 · start 2005-02

    Registered record
    Registry ID
    NCT00654576
    Conditions
    Schizophrenia
    Interventions
    Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole; psychosocial intervention
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-02
    Completion
    2007-12
    Enrolment
    1,400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionChlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole; psychosocial intervention
    PhasePhase 4
    Registry statusCompleted